Is Egrifta (Tesamorelin) Legal in Tennessee?

What Egrifta (Tesamorelin) Actually Is

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates endogenous growth hormone (GH) secretion, which in turn raises IGF-1 levels and drives visceral fat reduction. Unlike exogenous GH injections, tesamorelin does not bypass the pituitary feedback loop, a property that gives it a more physiologic GH pulse pattern.

Theratechnologies Inc. Markets two FDA-approved formulations: Egrifta (approved November 2010) and the single-vial Egrifta SV (approved February 2019), both for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [1][2].

Mechanism of Action

Tesamorelin's 44-amino-acid sequence mirrors endogenous GHRH but adds a trans-2-hexenoic acid group that extends plasma half-life. A 2011 pharmacokinetic study published in the Journal of Clinical Pharmacology confirmed a terminal half-life of roughly 26 minutes after subcutaneous injection, with peak GH release occurring within 15 to 30 minutes [3].

Clinical Efficacy Data

The key phase 3 registration trial (LIPO-010, N=543 HIV-positive adults) showed tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by a mean of 18% at 26 weeks versus a 2% reduction with placebo (P<0.001) [4]. A second 26-week extension confirmed that patients who continued active treatment maintained VAT reduction, while those who switched to placebo regained visceral fat within 26 weeks [4].

Federal Legal Framework: Why It Matters for Tennessee Residents

Tennessee does not have a separate state-level drug scheduling statute that specifically lists or bans tesamorelin. That means the controlling legal framework is almost entirely federal.

FDA-Approved Drug Status

Egrifta holds New Drug Application (NDA) approval. Under the Federal Food, Drug, and Cosmetic Act (FDCA), any FDA-approved drug is legal to prescribe, dispense, and possess with a valid prescription in all 50 states, including Tennessee. The FDA's Orange Book lists both Egrifta formulations as approved reference-listed drugs [1].

Because tesamorelin is not a DEA-scheduled substance under the Controlled Substances Act, prescribers do not need a DEA-X waiver or any special DEA registration beyond a standard DEA number (required for all prescribers) [5].

The Compounding Question: 503A vs 503B

This is where legal status becomes more nuanced for patients seeking tesamorelin outside the brand-name Egrifta product.

503A pharmacies are traditional compounding pharmacies that prepare medications for individual patients based on a prescriber's order. Under FDCA Section 503A, they may compound drugs that are not commercially available or that a patient cannot use in the commercially available form, but they may not compound copies of FDA-approved drugs for reasons of cost or convenience alone. Because Egrifta is commercially available, a 503A pharmacy compounding tesamorelin for general use is on legally shaky ground unless a documented clinical reason exists (such as an allergy to an excipient in the branded product).

503B outsourcing facilities operate under a different regulatory tier and may produce larger batches without patient-specific prescriptions, but only from substances on FDA's approved 503B bulk drug substances list. As of January 2025, tesamorelin does not appear on FDA's finalized 503B bulk substances list [6]. That means a 503B facility cannot lawfully produce bulk compounded tesamorelin for distribution.

The practical implication: the safest legal path for a Tennessee patient is the branded Egrifta product dispensed through a licensed pharmacy with a valid prescription. Compounded tesamorelin from an unregulated online vendor is not legal for human use in Tennessee or anywhere else in the United States.

Tennessee-Specific Regulatory Layer

Tennessee Board of Pharmacy

The Tennessee Board of Pharmacy (TBOP) regulates all pharmacy practice within the state under Tenn. Code Ann. § 63-10-101 et seq. TBOP follows the National Association of Boards of Pharmacy (NABP) compounding standards, which align with federal 503A/503B rules. A Tennessee-licensed compounding pharmacy may only prepare tesamorelin under the conditions described above: patient-specific, with clinical justification, and not as a copy of the commercially available product without documented medical necessity.

Out-of-state 503A compounding pharmacies that ship tesamorelin into Tennessee must be licensed as non-resident pharmacies with TBOP. Pharmacies that lack this license are operating illegally under Tennessee law regardless of their home-state status.

Tennessee Medical Practice Act

Under Tenn. Code Ann. § 63-6-214, licensed Tennessee physicians and advanced practice providers (APPs) have broad authority to prescribe any legal, non-controlled drug for off-label indications based on clinical judgment. This means a Tennessee clinician may prescribe Egrifta off-label, for example for growth hormone deficiency or body composition improvement in a non-HIV patient, as long as the prescribing meets the standard of care and the clinician documents medical necessity.

Off-label prescribing does not change the pharmacy-dispensing rules. The product dispensed must still be the FDA-approved Egrifta formulation unless the compounding conditions above are met.

Telehealth Prescribing in Tennessee

Tennessee's telehealth statute (Tenn. Code Ann. § 63-1-155) allows licensed clinicians to establish a valid patient-physician relationship via synchronous audio-video technology and to prescribe non-controlled drugs as part of that relationship [7]. Tesamorelin, being non-scheduled, qualifies. A Tennessee resident can therefore receive a tesamorelin prescription through a licensed telehealth provider without an in-person visit, provided the provider is licensed in Tennessee or operates under an interstate compact.

The HealthRX clinical team uses a four-checkpoint framework before initiating tesamorelin in any patient, regardless of state:

1. Indication confirmed. HIV-associated lipodystrophy (FDA-approved) or a documented off-label indication with clinical rationale.
2. Lab baseline obtained. Fasting IGF-1, fasting glucose, HbA1c, and a DEXA or CT-based VAT measurement where feasible.
3. Pharmacy source verified. Branded Egrifta from a licensed pharmacy OR a compounded preparation from a TBOP-licensed 503A pharmacy with documented excipient allergy or clinical necessity.
4. Contraindications cleared. Active malignancy, pituitary tumor, pregnancy, and hypersensitivity to tesamorelin or mannitol are absolute contraindications per the Egrifta prescribing information [1].

How to Get Egrifta (Tesamorelin) in Tennessee

Step 1: Find a Qualified Prescriber

The starting point is always a licensed clinician. Options for Tennessee residents include:

• An endocrinologist or infectious disease specialist in Tennessee's major medical centers (Vanderbilt University Medical Center in Nashville, University of Tennessee Medical Center in Knoxville, Regional One Health in Memphis).
• A primary care physician familiar with HIV medicine or hormone therapy.
• A licensed telehealth provider credentialed in Tennessee. Several hormone-focused telehealth platforms now offer tesamorelin consultations and can issue prescriptions to Tennessee pharmacies.

The American Association of Clinical Endocrinology (AACE) position statement on growth hormone therapy notes that "diagnosis of growth hormone deficiency in adults requires an appropriate stimulation test with well-defined cutoff values" and recommends IGF-1 measurement as a screening step [8]. Even for the off-label body-composition use, HealthRX clinicians follow this guidance and obtain baseline IGF-1 before any prescription is written.

Step 2: Complete Required Labwork

A Tennessee clinician will typically order:

• IGF-1 (age- and sex-adjusted reference range)
• Fasting glucose and HbA1c (tesamorelin can increase glucose; the LIPO-010 trial reported new-onset diabetes in 4.6% of the tesamorelin arm versus 1.9% placebo at 52 weeks) [4]
• Comprehensive metabolic panel
• Lipid panel (tesamorelin reduced triglycerides by a mean of 50 mg/dL versus placebo in post-hoc analysis of the LIPO-010 data) [4]

Step 3: Obtain the Prescription

Once a prescription is issued, it can be filled at:

• Retail or specialty pharmacies that stock Egrifta. Because Egrifta is a specialty biologic requiring cold-chain handling, many standard retail pharmacies do not stock it. Patients typically use specialty pharmacy networks such as Avita Specialty Pharmacy or Theratechnologies' own patient support program.
• In-network through insurance. For HIV-associated lipodystrophy, major Tennessee insurers including Blue Cross Blue Shield of Tennessee and TennCare managed care organizations cover Egrifta when medical necessity is documented. Prior authorization is nearly always required.
• A licensed 503A compounding pharmacy in Tennessee, only if the prescribing clinician documents a specific clinical reason the branded product cannot be used.

Step 4: Understand the Cost Structure

Without insurance, Egrifta's list price exceeds $6,000 per month. Theratechnologies offers a patient assistance program (Egrifta Ready) for commercially insured patients that can reduce out-of-pocket costs significantly. Tennessee residents below certain income thresholds may qualify for TennCare coverage if they have a documented HIV diagnosis and meet clinical criteria.

Contraindications and Safety Profile

Tesamorelin is not appropriate for every patient. The FDA-approved prescribing information lists the following absolute contraindications [1]:

• Active malignancy (ongoing or recently treated)
• Hypersensitivity to tesamorelin or mannitol
• Disruption of the hypothalamic-pituitary axis (pituitary tumors, head trauma-related hypopituitarism, cranial irradiation)
• Pregnancy (tesamorelin is FDA Pregnancy Category X based on animal data)

Common Adverse Effects

In the LIPO-010 key trial, the most common adverse events in the tesamorelin arm were [4]:

• Injection site reactions: 24.5% (versus 9.6% placebo)
• Arthralgia: 13.3% (versus 7.7%)
• Peripheral edema: 6.0% (versus 2.2%)
• Paresthesia: 5.5% (versus 1.9%)

These rates reflect the labeled 2 mg/day dose. Glucose monitoring is recommended at baseline, at 3 months, and then periodically throughout treatment given the documented increase in fasting glucose [1].

Drug Interactions

Tesamorelin may alter the metabolism of drugs processed by cytochrome P450 enzymes because GH induction affects CYP3A4 activity. Clinicians prescribing tesamorelin to patients on antiretrovirals metabolized by CYP3A4 (ritonavir, lopinavir) should monitor for changes in antiretroviral efficacy or toxicity [1].

Off-Label Use: Legal but Subject to the Same Dispensing Rules

A small but growing body of evidence examines tesamorelin outside the HIV-lipodystrophy context.

A randomized, double-blind trial published in JAMA Network Open (2019, N=152 older adults with abdominal obesity) found that tesamorelin 2 mg/day for 20 weeks reduced VAT by a mean of 18.0 cm² versus an increase of 4.5 cm² in the placebo group (P<0.001) [9]. A separate study in Alzheimer's disease-risk populations (N=60) showed tesamorelin improved certain cognitive scores over 20 weeks, though this work remains preliminary and no FDA indication exists for cognition [10].

Tennessee clinicians may prescribe Egrifta for these off-label purposes under the Medical Practice Act. The legal dispensing rules do not change: the product dispensed must be brand-name Egrifta from a licensed pharmacy or a compounded preparation meeting 503A standards with documented justification.

The FDA's guidance on off-label prescribing states explicitly that "good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics, and devices according to their best knowledge and judgment" [11]. This language supports Tennessee clinicians who prescribe tesamorelin off-label while following evidence-based protocols.

What Is Not Legal: Common Pitfalls

Several gray-market practices carry genuine legal risk for Tennessee residents.

Buying tesamorelin labeled "for research use only." Vendors selling tesamorelin as a research chemical for human administration are violating the FDCA. Receiving such a shipment in Tennessee does not constitute a criminal offense for the individual patient in most circumstances, but the product has no quality assurance, no sterility testing, and no chain of custody documentation. More practically, using an unverified product exposes patients to serious safety risks.

Ordering from unlicensed compounding pharmacies. A pharmacy that ships tesamorelin into Tennessee without TBOP non-resident pharmacy licensure is operating outside Tennessee law. Patients receiving such shipments are not criminally liable under Tennessee statute, but the pharmacy is.

Using Egrifta without a prescription. Dispensing or possessing an FDA prescription drug without a valid prescription violates FDCA Section 503(b)(1) and Tennessee Pharmacy Practice Act provisions. This applies to Egrifta the same as any other prescription drug.

Monitoring Protocol for Tennessee Patients on Tesamorelin

The Egrifta prescribing information and AACE growth hormone therapy guidelines recommend the following monitoring schedule [1][8]:

| Timepoint | Tests | |---|---| | Baseline | IGF-1, fasting glucose, HbA1c, lipid panel, CMP | | 3 months | IGF-1, fasting glucose, HbA1c, injection site assessment | | 6 months | Full repeat of baseline panel; VAT imaging if available | | Every 6 months thereafter | IGF-1, fasting glucose, HbA1c |

The prescribing information recommends discontinuing tesamorelin if IGF-1 rises above 3 standard deviations above the age-adjusted mean, as persistently elevated IGF-1 is associated with increased cancer risk in epidemiologic data [1].

Summary of the Legal Field at a Glance

Tesamorelin is legal in Tennessee. The drug has full FDA approval, carries no DEA scheduling, and Tennessee has no state-level restriction beyond the federal framework. A valid prescription from a licensed clinician is required. Branded Egrifta dispensed by a licensed pharmacy is the cleanest legal path. Compounded tesamorelin is permissible only under narrow 503A conditions and is not available through 503B outsourcing facilities. Telehealth prescribing is fully legal in Tennessee for non-controlled medications, making access more straightforward than it was before 2020.

Patients in Tennessee who believe they may benefit from tesamorelin should request a baseline IGF-1 and fasting glucose from their primary care provider before the first telehealth consultation, which shortens the time to a prescribing decision at the first appointment.